Bowling Portfolio Management LLC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 94.0% in the first quarter, Holdings Channel.com reports. The fund owned 349 shares of the medical research company’s stock after selling 5,504 shares during the quarter. Bowling Portfolio Management LLC’s holdings in Thermo Fisher Scientific were worth $206,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in TMO. Norges Bank acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $2,784,029,000. BlackRock Inc. lifted its position in shares of Thermo Fisher Scientific by 3.8% during the 4th quarter. BlackRock Inc. now owns 30,982,611 shares of the medical research company’s stock valued at $20,672,838,000 after acquiring an additional 1,143,333 shares during the last quarter. Marshall Wace LLP lifted its position in shares of Thermo Fisher Scientific by 146.4% during the 4th quarter. Marshall Wace LLP now owns 1,043,844 shares of the medical research company’s stock valued at $696,497,000 after acquiring an additional 620,291 shares during the last quarter. Liontrust Investment Partners LLP acquired a new stake in shares of Thermo Fisher Scientific during the 3rd quarter valued at $311,726,000. Finally, State Street Corp lifted its holdings in shares of Thermo Fisher Scientific by 3.4% in the fourth quarter. State Street Corp now owns 16,223,173 shares of the medical research company’s stock valued at $10,828,875,000 after purchasing an additional 529,712 shares in the last quarter. Institutional investors own 87.48% of the company’s stock.
In related news, COO Michel Lagarde sold 13,030 shares of Thermo Fisher Scientific stock in a transaction dated Friday, May 27th. The stock was sold at an average price of $565.04, for a total transaction of $7,362,471.20. Following the sale, the chief operating officer now directly owns 15,758 shares of the company’s stock, valued at $8,903,900.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Debora L. Spar sold 200 shares of Thermo Fisher Scientific stock in a transaction dated Monday, May 2nd. The stock was sold at an average price of $544.36, for a total value of $108,872.00. Following the sale, the director now directly owns 810 shares in the company, valued at $440,931.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 42,561 shares of company stock worth $23,557,413. 0.43% of the stock is owned by company insiders.
Thermo Fisher Scientific (NYSE:TMO – Get Rating) last issued its quarterly earnings results on Thursday, April 28th. The medical research company reported $7.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.17 by $1.08. The company had revenue of $11.82 billion for the quarter, compared to the consensus estimate of $10.66 billion. Thermo Fisher Scientific had a return on equity of 25.33% and a net margin of 18.49%. The firm’s revenue was up 19.3% compared to the same quarter last year. During the same period last year, the business posted $7.21 earnings per share. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 22.7 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, July 15th. Investors of record on Wednesday, June 15th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 0.23%. The ex-dividend date is Tuesday, June 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.26%.
A number of analysts have recently issued reports on the company. StockNews.com assumed coverage on Thermo Fisher Scientific in a report on Thursday, March 31st. They issued a “hold” rating for the company. Wells Fargo & Company lowered Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and reduced their target price for the company from $605.00 to $525.00 in a report on Monday, April 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $658.92.
Thermo Fisher Scientific Profile (Get Rating)
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
- Get a free copy of the StockNews.com research report on Thermo Fisher Scientific (TMO)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.